US facility · Biopharma manufacturing
Fujifilm adds $1.2 billion to its North Carolina biologics plant
- Company
- Fujifilm (Tokyo)
- Project
- Fujifilm Diosynth Biotechnologies Holly Springs site, Holly Springs, North Carolina
- Value
- $1.2B (total site investment over $3.2B)
- Status
- Under way. The site's first phase of eight bioreactors opened in September 2025; the eight added by this investment are still to come, targeted by 2028.
- Date
- 2024-04-12
Fujifilm said it would put another $1.2 billion into its contract biologics manufacturing site in Holly Springs, adding eight 20,000-liter mammalian cell culture bioreactors. The move lifts total investment in the site above $3.2 billion and was to add 680 jobs, for about 1,400 in all. The announcement came on the eve of Prime Minister Kishida's visit to North Carolina during his April 2024 state visit.
Why it matters
It is a large Japanese manufacturing commitment in the US and shows Fujifilm betting on demand for outsourced production of biologic drugs.
The investment
The April 12, 2024 plan adds eight bioreactors on top of the eight already planned, for 16 in all, with the new ones due by 2028. The 680 new jobs are due by 2031, backed by a 12-year North Carolina job grant. Fujifilm builds identical large plants in the US and Europe under its "kojoX" model, so drugmakers can run the same process at either site.
Big customers
In April 2025, Regeneron signed a 10-year manufacturing agreement worth more than $3 billion to make its biologic drugs at Holly Springs. Regeneron said the deal would nearly double its large-scale US manufacturing capacity. Johnson & Johnson said the site lets it expand its US production.
Opening
The site held its grand opening on September 24, 2025 and calls itself one of the largest commercial-scale cell culture plants in North America. It had more than 680 workers and aims for 1,400 by 2031. Finished-product capacity is due in 2026.
Sources
Kakehashi M&A News home
